Nombramiento de Director Financiero
Farmacéutica Faron Oy
("Faron o la "Compañía")
Insider Information: Appointment of Chief Financial Officer
Company announcement, Información interna
15 April 2024 at 2:00 a.m. EDT / 7:00 a.m. BST / 9:00 a.m. EEST
TURKU, FINLANDIA / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces the appointment of Yrjö Wichmann as the Company's interim Chief Financial Officer (CFO), effective 15 April, 2024. Mr. Wichmann succeeds James O'Brien, who is leaving Faron to pursue another career opportunity.
Mr. Wichmann served as the Company's CFO between 2014 and 2019 and is an accomplished biotech and financial executive with over 20 years' experience in financing and investment banking. Most recently, Mr. Wichmann has served as Senior Vice President, Financing & IR at Faron. Prior to his roles at Faron, Mr Wichmann held a number of senior positions within the life sciences and biotechnology sector at IP Finland Oy, Biohit Oyj (NASDAQ OMX Helsinki), CapMan Oyj, FibroGen Europe Oyj (NASDAQ) and D. Carnegies & Co AB. He is a member of the Investment Committee at Dasos Timberland Fund I and II and a board member at Nordic Science Investment Oy. Mr Wichmann holds a Master's in Economics from Helsinki University.
"As a former CFO of this Company and, most recently, our Vicepresidente sénior Financing & IR, Yrjö is well positioned to take up the role of Interim CFO whilst we look for a permanent replacement." said Chief Executive Officer of Faron, Dr. Markku Jalkanen. "On behalf of the Board, I would like to thank Jim for his service to Faron. His contributions, during very challenging market conditions, have been considerable and very much appreciated, and we wish him all the best in his next role."
Mr. Wichmann, incoming Interim Chief Financial Officer said: "As we continue to progress our ambitious program for bexmarilimab, my priority is to advance a financing plan that will secure our cash runway and enable the rapid development of this important, novel immunotherapy, which has enormous potential for patients and shareholders. I look forward to working with Markku, the Board and incoming CEO, Juho Jalkanen, to deliver on our next milestones."
James O'Brien, outgoing Chief Financial Officer, said: "During my time at Faron, I have been impressed by the strength of its science and by the professionalism and unwavering commitment of the team, and I continue to believe in the potential of bexmarilimab to provide a new, safe and effective treatment option for patients suffering from aggressive cancers. I wish the team great success for the future."
Para más información, por favor contacte:
Farmacéutica Faron
Contacto con inversores
Asesores LifeSci
Ferry de Daniel
Director General
+1 (617) 430-7576
Consejo ICR
Mary-Jane Elliott, David Daley, Lindsey Neville
Teléfono: + 44 (0) 20 3709 5700
E-mail: GME@dhr-rgv.com
Cairn Financial Advisors LLP, nómada
Sandy Jamieson, Jo Turner
Teléfono: + 44 (0) 207 213 0880
pelar caza llp, Broker
christopher dorado, james acero
Teléfono: + 44 (0) 20 7418 8900
Sisu Partners Oy, asesor certificado en Nasdaq First North
Juha Kartunen
Teléfono: + 358 (0) 40 555 4727
Jukka Järvelä
Teléfono: + 358 (0) 50 553 8990
Acerca de Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) es una empresa biofarmacéutica global en etapa clínica, centrada en abordar el cáncer a través de nuevas inmunoterapias. Su misión es llevar la promesa de la inmunoterapia a una población más amplia mediante el descubrimiento de formas novedosas de controlar y aprovechar el poder del sistema inmunológico. El activo principal de la Compañía es bexmarilimab, un nuevo anticuerpo humanizado anti-Clever-1, con el potencial de eliminar la inmunosupresión de los cánceres al atacar la función de las células mieloides. bexmarilimab está siendo investigado en ensayos clínicos de Fase I/II como terapia potencial para pacientes con cánceres hematológicos en combinación con otros tratamientos estándar y como monoterapia en cánceres sólidos de última línea. Más información está disponible en www.faron.com.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.